Abstract
As the demand for CAR T cell cancer therapy increases, several closed and automated production platforms are being deployed, and others are in development.This review provides a critical appraisal of these technologies that can be leveraged to scale and optimize the production of next generation CAR T cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have